FY2025 EPS Estimates for Bruker Cut by Leerink Partnrs

Key Points

• Leerink Partners has lowered their FY2025 earnings per share estimate for Bruker Corporation from $2.01 to $1.95, with a consensus estimate for the full year currently at $2.69.
• Bruker's quarterly earnings missed expectations, reporting $0.32 EPS against a consensus of $0.33 EPS, with revenue falling short of estimates at $797.40 million.
• The company's stock has a current market capitalization of $5.54 billion and is rated as "Hold" by the majority of analysts, with an average target price of $51.00.

Bruker Corporation (NASDAQ:BRKR - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Bruker in a research report issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $1.95 for the year, down from their prior estimate of $2.01. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker's Q4 2025 earnings at $0.83 EPS, Q1 2026 earnings at $0.46 EPS, Q3 2026 earnings at $0.56 EPS, Q4 2026 earnings at $0.88 EPS, FY2026 earnings at $2.34 EPS and FY2027 earnings at $2.69 EPS.

Other equities research analysts have also recently issued reports about the company. Citigroup lowered their target price on Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, August 4th. Barclays cut their price target on Bruker from $43.00 to $40.00 and set an "overweight" rating on the stock in a research note on Thursday, October 2nd. Weiss Ratings reiterated a "sell (d+)" rating on shares of Bruker in a report on Wednesday, October 8th. Bank of America dropped their price objective on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Finally, Stifel Nicolaus set a $40.00 price objective on Bruker and gave the company a "hold" rating in a report on Tuesday, August 5th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $51.00.

Bruker Trading Up 0.8%

BRKR stock opened at $36.52 on Wednesday. The business has a fifty day moving average price of $33.10 and a 200 day moving average price of $37.06. Bruker has a fifty-two week low of $28.53 and a fifty-two week high of $65.25. The stock has a market capitalization of $5.54 billion, a price-to-earnings ratio of 70.23, a P/E/G ratio of 5.05 and a beta of 1.20. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The company had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. During the same period in the previous year, the company posted $0.52 earnings per share. The company's quarterly revenue was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd were issued a dividend of $0.05 per share. The ex-dividend date was Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Insider Activity

In related news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the transaction, the director directly owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 27.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BRKR. Fifth Third Bancorp grew its holdings in shares of Bruker by 54.2% during the first quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock worth $46,000 after buying an additional 390 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Bruker by 81.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 29,826 shares of the medical research company's stock valued at $1,245,000 after purchasing an additional 13,367 shares in the last quarter. Rakuten Securities Inc. bought a new position in Bruker in the first quarter valued at approximately $167,000. Lecap Asset Management Ltd. bought a new position in Bruker in the first quarter valued at approximately $2,714,000. Finally, Wealthquest Corp bought a new position in Bruker in the first quarter valued at approximately $143,000. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.